stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Return on assets
HUTCHMED (China) Limited Sponsored ADR's return on assets over the twelve months to 30 June 2026 was 0.00%, down 30.2 percentage points from fiscal 2025 (30.2%). Over the past ten years it has ranged from −30.0% (fiscal 2022) to 30.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 30.2% | 27.24 |
| FY2024 | 2.95% | (5.78) |
| FY2023 | 8.73% | 38.77 |
| FY2022 | −30.0% | (11.47) |
| FY2021 | −18.6% | 2.57 |
| FY2020 | −21.1% | 0.12 |
| FY2019 | −21.3% | (8.02) |
| FY2018 | −13.2% | (7.55) |
| FY2017 | −5.69% | (9.78) |
| FY2016 | 4.09% | 19.99 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ANIP ANI Pharmaceuticals, Inc. compare | 7.85% |
| PBH Prestige Consumer Healthcare Inc. compare | 3.80% |
| HCM HUTCHMED (China) Limited Sponsored ADR | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −1.64% |
| TRLV Trulieve Cannabis Corp. compare | −17.6% |
| PRGO Perrigo Company plc compare | −20.2% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −69.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement